Immunobiogram ® (IMBG) is a first-in-class pharmacodynamic immunoassay that provides the sensitivity/resistance profile of each patient to a panel of IMS tested and has the potential to help clinicians to individualize IMS treatment adjustment.
IMBG has been tested for Kidney Transplantation (KT) in two clinical studies that belong to the TRANSBIO Project (Cellular BIOtechnology for prognosis and monitoring in renal TRANSplantation), supported by the European Union Horizon 2020 Programme for Research and Innovation as a SME instrument Phase 2 under grant agreement Nº 733248:
TRANSBIO STUDY is an international, multicenter clinical study performed to confirm BH-Pilot 2015 results and to achieve the technical validation of the IMBG. It was performed in nine major University Hospitals in Europe and USA with more than 200 patients recruited.
The study objectives were to evaluate IMBG robustness, the association with clinical prognoses and its consistency in Kidney Transplantation (KT).
The studies show these results: